← Back to Search

Botanical-based drug

NBT-NM108 for Coronavirus (COVGUT20 Trial)

Phase 2
Waitlist Available
Led By Asa Oxner, MD
Research Sponsored by Notitia Biotechnologies Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at days 0, 14, 28, and 56
Awards & highlights

COVGUT20 Trial Summary

This trial will test a new botanical-based drug to see if it is effective in treating early-stage COVID-19 patients.

Eligible Conditions
  • Coronavirus

COVGUT20 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at days 0, 14, 28, and 56
This trial's timeline: 3 weeks for screening, Varies for treatment, and at days 0, 14, 28, and 56 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Gut Microbiota Composition
Secondary outcome measures
Body temperature (F)
Fasting blood glucose (mg/dl)
Illness severity based on the categorization from FDA COVID-19 Guidance Document
+9 more

COVGUT20 Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: NBT-NM108 + Usual CareExperimental Treatment1 Intervention
Group II: Usual Care OnlyActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
NBT-NM108
2023
Completed Phase 2
~60

Find a Location

Who is running the clinical trial?

Notitia Biotechnologies CompanyLead Sponsor
University of South FloridaOTHER
408 Previous Clinical Trials
186,802 Total Patients Enrolled
Rutgers UniversityOTHER
113 Previous Clinical Trials
2,804,049 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
NBT-NM108 as an Early Treatment for Suspected or Confirmed Symptomatic COVID-19 Patients
2021. "NBT-NM108 as an Early Treatment for Suspected or Confirmed Symptomatic COVID-19 Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04540406.
~13 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top